Finding an optimal treatment for any disease is impossible until we fully understand its cause. We believe the central problem in obtaining this understanding is that the most commonly proposed models for amyloid aggregation may be incorrect, and that the process is not fundamentally biological. We plan to investigate the pathways and kinetics of protein aggregation to allow accurate predictive modeling of the process and evaluation of potential inhibitors to prevalent diseases including cataract formation, chronic traumatic encephalopathy, Alzheimer's Disease, Parkinson's Disease and others. The goal of the Protein Colloidal Aggregation project is to understand the underlying cause of several major diseases, including Alzheimer's, Parkinson's, and chronic traumatic encephalopathy. These diseases all occur when protein molecules undergo a peculiar and irreversible process in which they aggregate to form tiny fibers of a unique material called amyloid, which the body cannot remove. Despite enormous investment in research, the fundamental physiochemical mechanism of these diseases remains poorly understood. Based on initial studies using atomic force microscopy (AFM), we theorized that the aggregation of proteins in these diseases is driven instead by colloidal interactions, the same forces that govern the behavior of nanoscale particles in the colloidal suspensions we encounter every day, such as paint, milk, and clouds. Our theory is being validated by the evidence. For many years, NASA has been heavily involved in research into the structure of proteins and their assembly into crystals, and in studying the colloidal interactions and aggregation of nanoscale particles. To date, however, NASA's colloid research has involved only nonbiological materials. But now we are bridging these two fields by studying the colloidal aggregation of proteins.